-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to Its Board of Directors
Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to Its Board of Directors
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companies
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.
Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and extensive expertise in product development, regulatory approval, commercial activities, and a track record of delivering substantial value for stockholders. Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi™, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy.
Professor Lawrence Steinman, Chairman of the Board of Pasithea, stated, "We are pleased to welcome Mr. Novak to our Board of Directors. We are thrilled that an individual of Al's caliber has joined Pasithea's Board and his input will be invaluable as we continue our progress toward developing proprietary drug candidates and achieve value-creating milestones. The Board would like to express its appreciation to Dr. Bendiabdallah for all his dedication and contributions to Pasithea."
Mr. Novak commented, "Pasithea is an exciting company with a promising portfolio of assets, encouraging pre-clinical results for its lead drug candidates and a world recognized team of scientists. I am honored to join Pasithea's Board and will work with my fellow directors and the management team to develop novel and groundbreaking therapies to improve patients' lives and create shareholder value."
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company's Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Pasithea Therapeutics Corp. Media Contact
Caitlin Kasunich
KCSA
E: ckasunich@kcsa.com
Mr. Novak brings over 30 years of board and management experience at innovative life sciences companies
諾瓦克先生在創新的生命科學公司擁有30多年的董事會和管理經驗
MIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system ("CNS") disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the "Board"). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped down from the Board on September 14, 2022.
佛羅裏達州邁阿密海灘,9月環球通訊社2022年20日電專注於發現、研究和開發治療中樞神經系統疾病的新型有效療法的生物技術公司帕西西亞治療公司(納斯達克代碼:KTTA)(“帕西西亞”或“公司”)今天宣佈,任命阿爾弗雷德·J·諾瓦克為其董事會成員(“董事會”)。諾瓦克將接替亞辛·本迪亞布達拉博士,後者於2022年9月14日從董事會辭職。
Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies. Mr. Novak brings financial acumen and extensive expertise in product development, regulatory approval, commercial activities, and a track record of delivering substantial value for stockholders. Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi™, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy.
諾瓦克先生作為首席執行官和首席財務官擁有廣泛的運營經驗,並曾在幾家製藥和醫療設備公司的董事會任職。諾瓦克先生在產品開發、監管審批、商業活動方面擁有敏鋭的金融洞察力和廣泛的專業知識,並擁有為股東帶來可觀價值的記錄。諾瓦克曾擔任多瓦製藥公司董事的一員,後者以逾9億美元的價格被瑞典孤兒Biovitrum AB或SOBI™收購;擔任董事的董事兼Biosense的首席執行長,後者以4億美元的價格被強生收購;以及科迪斯公司的首席財務官,後者被強生以18億美元的價格收購。他在賓夕法尼亞大學沃頓商學院獲得MBA學位,主修醫療管理,並在美國商船學院獲得學士學位。
Professor Lawrence Steinman, Chairman of the Board of Pasithea, stated, "We are pleased to welcome Mr. Novak to our Board of Directors. We are thrilled that an individual of Al's caliber has joined Pasithea's Board and his input will be invaluable as we continue our progress toward developing proprietary drug candidates and achieve value-creating milestones. The Board would like to express its appreciation to Dr. Bendiabdallah for all his dedication and contributions to Pasithea."
Pasithea公司董事會主席勞倫斯·斯坦曼教授説:“我們很高興歡迎諾瓦克先生加入我們的董事會。我們對Al這樣有才華的人加入Pasithea公司董事會感到興奮,他的貢獻將是無價的,因為我們將繼續在開發專利候選藥物和實現創造價值的里程碑方面取得進展。董事會要對Bendiabdallah博士對Pasithea公司的所有奉獻和貢獻表示感謝。”
Mr. Novak commented, "Pasithea is an exciting company with a promising portfolio of assets, encouraging pre-clinical results for its lead drug candidates and a world recognized team of scientists. I am honored to join Pasithea's Board and will work with my fellow directors and the management team to develop novel and groundbreaking therapies to improve patients' lives and create shareholder value."
諾瓦克先生評論説:“Pasithea是一家令人興奮的公司,擁有前景看好的資產組合,它的主要候選藥物和世界公認的科學家團隊的臨牀前結果令人鼓舞。我很榮幸加入Pasithea董事會,並將與我的董事同事和管理團隊合作,開發新穎和突破性的療法,以改善患者的生活並創造股東價值。”
About Pasithea Therapeutics Corp.
Pasithea治療公司簡介
Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Pasithea治療公司是一家生物技術公司,專注於發現、研究和開發治療中樞神經系統(CNS)疾病的新的有效療法。Pasithea在神經科學和精神藥理學領域擁有一支經驗豐富的專家團隊,正在開發用於治療精神和神經疾病的新分子實體,包括肌萎縮側索硬化症(ALS)和多發性硬化症(MS)。Pasithea通過在診所和家庭環境中提供靜脈注射氯胺酮來滿足目前患有精神疾病的患者的需求。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law. Such forward-looking statements are subject to risks (including those set forth in the Company's Form 10-K for the fiscal year ended December 31, 2021, as amended, filed with the U.S. Securities and Exchange Commission) and uncertainties which could cause actual results to differ from the forward-looking statements.
本新聞稿包含構成“前瞻性陳述”的陳述。前瞻性陳述受許多條件的制約,其中許多條件不在公司的控制範圍之內。雖然公司相信這些前瞻性陳述是合理的,但不應過度依賴任何此類前瞻性陳述,這些前瞻性陳述是基於公司在本新聞稿發佈之日所掌握的信息。這些前瞻性陳述是基於當前的估計和假設,會受到各種風險和不確定性的影響,包括但不限於公司提交給美國證券交易委員會的報告中陳述的風險和不確定性。因此,實際結果可能會有很大不同。除法律要求外,本公司不承擔在本新聞稿發佈之日後因新信息、未來事件或其他原因而更新這些陳述的義務。此類前瞻性陳述會受到風險(包括公司在提交給美國證券交易委員會的經修訂的截至2021年12月31日的財政年度10-K表格中陳述的風險)和不確定性因素的影響,這些風險和不確定性可能會導致實際結果與前瞻性陳述不同。
Pasithea Therapeutics Corp. Company Contact
Pasithea治療公司聯繫人
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
蒂亞戈·里斯·馬奎斯博士
首席執行官
電子郵件:tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Pasithea治療公司投資者關係
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
麗莎·M·威爾遜
現場通信公司
T: 212-452-2793
電子郵箱:lwilson@insiteconi.com
Pasithea Therapeutics Corp. Media Contact
Pasithea治療公司媒體聯繫方式
Caitlin Kasunich
KCSA
E: ckasunich@kcsa.com
凱特琳·卡蘇尼奇
KCSA
電子郵箱:ckasunich@kcsa.com
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧